霍奇金淋巴瘤序贯化疗临床研究 |
| |
引用本文: | 童浩,贾霖,韩建军,高飞,王允,况小红. 霍奇金淋巴瘤序贯化疗临床研究[J]. 西部医学, 2008, 20(5): 1043-1044 |
| |
作者姓名: | 童浩 贾霖 韩建军 高飞 王允 况小红 |
| |
作者单位: | 绵阳市第三人民医院血液肿瘤科,四川,绵阳,621000 |
| |
摘 要: | 目的探讨初治的霍奇金淋巴瘤(HL)更为安全有效的化疗方案。方法对36例Ⅰ~Ⅳ期HL患者,用3周期COP方案(环磷酰胺+长春新碱+强的松),后用3周期ABVD方案(盐酸吡柔比星+博来霉素+长春新碱+氮烯米胺),完成6周期化疗后根据具体情况给予放疗。结果完成化疗后,完全缓解(CR)29例(80.6%),部份缓解(PR)4例(11.1%),稳定(SD)2例5.4%,进展(PD)1例(2.6%),1年总生存率91.7%,2年总生存率88.9%。结论HL采用COP方案3周期、ABVD方案3周期序贯化疗效果好,心肌损害、肝损害轻,肺纤维化发生风险小,价格低。
|
关 键 词: | 霍奇金淋巴瘤 药物疗法 联合化疗 |
Clinical research on Hodgkin''s lymphoma with sequential chemotherapy |
| |
Affiliation: | TONG Hao,JIA Lin,HAN Jian-jun,et al (Department of Hematology and Oncology,The Third Hospital of Mianyang, Mianyang 621000, Sichuan, China) |
| |
Abstract: | Objective To explore safe and effective chemotherapy on Hodgykin's lymphomas (HL). Methods 36 patients with HL were treated with COP (CPA + vincristine + prednisone) and ABVD (THP + Bleomytin + vincristine + Dacarbazine) for 3 course, respectively. Radiotherapy was used according the condition of the patients. Result The rate of completely remission ), partial remission, non-change and progression were 81% (29/36), 11% (4/ 36), 5.4% (2/36) and 2.6%(1/36), respectively. The survival rate 1 and 2 is 92% (33/36) and 88.9% (32/36), respectively. Conclusion It is effective, safe and cheap to treat HL with COP and ABVD for 3 course. |
| |
Keywords: | Hodgkin lymphomas Chemotherapy |
本文献已被 维普 万方数据 等数据库收录! |
|